Aurobindo Pharma recalls antidepressant with mislabeled dosage

Generic drugmaker Aurobindo Pharma USA is recalling its antidepressant drug Mirtazapine because of a labeling error. 

Advertisement

The affected lot was labeled as Mirtazapine 7.5 milligram, but it may contain 15 milligram tablets. The expiration date on lot 03119002A3 is March 2022. 

Taking a higher dose of the drug than expected may increase risk of sedation, nausea, increased reflexes, agitation, tremors and more, the company warned. 

The drugmaker is notifying distributors and is arranging for the return of the tablets.

More articles on pharmacy:

Amazon’s PillPack seeking to win over new insurers in 2020
Roche buys international rights to Sarepta’s Duchenne drug for $750M
Former Aegerion sales rep defrauded insurers, stole identities to push cholesterol drug

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Advertisement

Next Up in Pharmacy

  • A series of recent FDA safety actions, drug recalls, label updates and court rulings across pharmacy carry operational implications for…

Advertisement

Comments are closed.